Treatment costs and determinants in PM(2.5)-attributable respiratory diseases: evidence from Northern Thailand

PM2.5相关呼吸系统疾病的治疗成本及决定因素:来自泰国北部的证据

阅读:2

Abstract

BACKGROUND: Environmental issues related to air pollution in Southeast Asia have persisted for more than a decade, especially in Thailand. This study aims to estimate the treatment costs of respiratory diseases caused by exposure to ambient PM₂.₅ and to identify the factors that influence these costs. METHODS: This retrospective study analyzed secondary data on OPD and IPD respiratory disease treatment costs from government hospitals, along with ambient PM₂.₅ data from low-cost monitoring stations, to estimate the cost of illness across 25 districts in Chiang Mai during Thailand's fiscal year 2023. Economic cost was estimated using the Cost-of-Illness method formula: Economic Cost Loss = Health Impact × Treatment Cost. K-means cluster analysis was used to classify estimated costs into minimum, medium, and maximum cost scenarios. Multiple linear regression was applied to identify significantly associated factors with treatment cost. RESULTS: Under the maximum cost scenario identified through K-means cluster analysis stratification, the total treatment cost associated with an average PM₂.₅ concentration of 42.59 µg/m³ was 460,122.58 USD, averaging 41.62 USD per case. Each 1 µg/m³ increase in PM2.5 was associated with a cost rise ranging from 403.84 to 13,159.87 USD. Non-infectious respiratory diseases incurred costs approximately two times higher than infectious ones. The estimate of maximum treatment burden for respiratory disease cases was highest in urban areas, totaling 102,878.88 USD. The urban area showed a significantly higher cost of treatment both in OPD and IPD cases (p < 0.001). Moreover, higher healthcare levels and older age were associated with higher costs in OPD cases. In IPD cases, length of hospital stay was a significant predictor. CONCLUSIONS: Ambient PM₂.₅ exposure contributes significantly to the economic burden of respiratory diseases in polluted areas. These highlight the importance of pollution control policies and healthcare resource planning in high-risk areas. TRIAL REGISTRATION: not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。